Compare EMBC & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EMBC | CMPS |
|---|---|---|
| Founded | 1924 | 2020 |
| Country | United States | United Kingdom |
| Employees | 1850 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.7M | 778.7M |
| IPO Year | 2021 | 2020 |
| Metric | EMBC | CMPS |
|---|---|---|
| Price | $8.80 | $6.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $18.50 | ★ $27.14 |
| AVG Volume (30 Days) | 801.9K | ★ 4.5M |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | ★ 6.81% | N/A |
| EPS Growth | ★ 20.90 | 0.86 |
| EPS | ★ 0.74 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.17 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.77 | $2.25 |
| 52 Week High | $15.55 | $8.90 |
| Indicator | EMBC | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 31.39 | 43.07 |
| Support Level | N/A | $5.95 |
| Resistance Level | $10.88 | $7.02 |
| Average True Range (ATR) | 0.33 | 0.50 |
| MACD | -0.07 | -0.09 |
| Stochastic Oscillator | 1.03 | 3.93 |
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.